Former Chief Operating Officer · HOOKIPA Pharma Inc. (HOOK)

Christine Baker

A named executive officer of HOOKIPA Pharma in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$813,399

Salary $477,000Stock awards $0

FY2022: $873,624

2nd of 3 named executive officers at Hookipa Pharma by FY2023 total.

3 named officers on file for HOOKIPA Pharma, FY2023

Christine Baker’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how HOOKIPA Pharma’s whole pay program stands against its peers

  • HOOKIPA Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on HOOK→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Christine Baker’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Christine Baker compensation by year

HOOKIPA Pharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as HOOKIPA Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$394,263$477,000
Bonus$0$0
Stock awards$0$0
Option awards$263,104$151,479
Non-equity incentive$204,057$171,720
Pension and deferred compensation$0$0
All other$12,200$13,200
Total$873,624$813,399

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HOOKIPA Pharma Inc. DEF 14A filed April 26, 2024, accession 0001104659-24-052900, and prior-year filings. Open the filing on EDGAR.

How this page was built: the HOOKIPA Pharma Inc. filed document, accession 0001104659-24-052900. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$874K
$813K
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option275,800—$1.00
Option3,781—$8.03
Option15,609—$12.00
Option56,250—$1.66
Option56,250—$1.66

Per the Outstanding Equity Awards at Fiscal Year-End table in HOOKIPA Pharma Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

HOOKIPA Pharma’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Joern AldagChief Executive Officer$1,130,427
Christine Baker · this pageFormer Chief Operating Officer$813,399
Reinhard KanderaChief Financial Officer$725,475

The full HOOKIPA Pharma compensation record

free company brief

This page is one person within HOOKIPA Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HOOKIPA Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christine Baker's compensation dossier · One-time report. No refunds.